Optimization of Prime-Boost Vaccination Strategies Against Mouse-Adapted Ebolavirus in a Short-Term Protection Study

Journal of Infectious Diseases

Volumn 212, Issue , 2015, Pages S389-S397

  Aviles, Jenna ^a,b   Bello, Alexander ^a,b   Wong, Gary ^a,b   Fausther Bovendo, Hugues ^a,b   Qiu, Xiangguo ^a,b   Kobinger, Gary ^a,b  

^a PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

Author keywords

adeno associated virus; adenovirus; DNA; Ebola virus; prime boost; vaccine

Indexed keywords

EBOLA VACCINE; GAMMA INTERFERON; IMMUNOGLOBULIN G ANTIBODY; NEUTRALIZING ANTIBODY; PARVOVIRUS VECTOR; VIRUS GLYCOPROTEIN; GLYCOPROTEIN; IMMUNOGLOBULIN G; VIRUS ANTIBODY; VIRUS PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; EBOLA HEMORRHAGIC FEVER; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; HUMAN ADENOVIRUS 5; MOUSE; NONHUMAN; PORCINE ADENOVIRUS A; PRIORITY JOURNAL; ANIMAL; CELLULAR IMMUNITY; DEPENDOPARVOVIRUS; EBOLAVIRUS; GENE VECTOR; HUMAN; HUMAN ADENOVIRUS C; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOLOGY; PIG; PROCEDURES; VACCINATION; VIROLOGY;

ADENOVIRUSES, HUMAN; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; DEPENDOVIRUS; EBOLA VACCINES; EBOLAVIRUS; ENZYME-LINKED IMMUNOSORBENT ASSAY; ENZYME-LINKED IMMUNOSPOT ASSAY; GENETIC VECTORS; GLYCOPROTEINS; HEMORRHAGIC FEVER, EBOLA; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNIZATION, SECONDARY; IMMUNOGLOBULIN G; MICE; SWINE; VACCINATION; VIRAL PROTEINS;

EID: 84941312280     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiv175     Document Type: Article

References (42)

1. Feldmann H, Geisbert TW. Ebola haemorrhagic fever. Lancet 2011; 377:849-62.
2. Richardson Jason S, Dekker Joseph D, Croyle Maria A, Kobinger Gary P. Recent advances in Ebolavirus vaccine development. Hum Vaccin 2010; 6:439-49.
3. Sullivan Nancy J, Geisbert Thomas W, Geisbert Joan B, et al. Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature 2003; 424:681-4.
4. Swenson DL, Wang D, Luo M, et al. Vaccine to confer to nonhuman primates complete protection against multistrain Ebola and Marburg virus infections. Clin Vaccine Immunol 2008; 15:460-7.
5. Pratt William D, Wang D, Nichols Donald K, et al. Protection of nonhuman primates against two species of Ebola virus infection with a single complex adenovirus vector. Clin Vaccine Immunol 2010; 17:572-81.
6. Jones SM, Feldmann H, Ströher U, et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med 2005; 11:786-90.
7. Warfield Kelly L, Swenson Dana L, Olinger Gene G, Kalina Warren V, Aman MJ, Bavari S. Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge. J Infect Dis 2007; 196(suppl):S430-7.
8. Bukreyev A, Rollin Pierre E, Tate Mallory K, et al. Successful topical respiratory tract immunization of primates against Ebola virus. J Virol 2007; 81:6379-88.
9. DiNapoli Joshua M, Yang L, Samal Siba K, Murphy Brian R, Collins Peter L, Bukreyev A. Respiratory tract immunization of non-human primates with a Newcastle disease virus-vectored vaccine candidate against Ebola virus elicits a neutralizing antibody response. Vaccine 2010; 29:17-25.
10. Blaney Joseph E, Marzi A, Willet M, et al. Antibody quality and protection from lethal Ebola virus challenge in nonhuman primates immunized with rabies virus based bivalent vaccine. PLoS Pathog 2013; 9: e1003389.
11. Mire Chad E, Geisbert Joan B, Agans Krystle N, et al. Durability of a vesicular stomatitis virus-based Marburg virus vaccine in nonhuman primates. PLoS One 2014; 9:e94355.
12. Sullivan NJ, Sanchez A, Rollin PE, Yang ZY, Nabel GJ. Development of a preventive vaccine for Ebola virus infection in primates. Nature 2000; 408:605-9.
13. Stanley Daphne A, Honko Anna N, Asiedu C, et al. Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge. Nat Med 2014; 20:1126-9.
14. Thacker Erin E, Timares L, Matthews Qiana L. Strategies to overcome host immunity to adenovirus vectors in vaccine development. Expert Rev Vaccines 2009; 8:761-77.
15. Barouch Dan H, Pau Maria G, Custers Jerome H, et al. Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of preexisting anti-Ad5 immunity. J Immunol 2004; 172:6290-7.
16. Ledgerwood JE, Costner P, Desai N, et al. A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults. Vaccine 2010; 29:304-13.
17. Buchbinder Susan P, Mehrotra Devan V, Duerr A, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): A double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008; 372:1881-93.
18. Capone S, D'Alise Anna M, Ammendola V, et al. Development of chimpanzee adenoviruses as vaccine vectors: challenges and successes emerging from clinical trials. Expert Rev Vaccines 2013; 12:379-93.
19. Choi Jin H, Schafer Stephen C, Zhang L, et al. A single sublingual dose of an adenovirus-based vaccine protects against lethal Ebola challenge in mice and guinea pigs. Mol Pharm 2012; 9:156-67.
20. Richardson Jason S, Pillet S, Bello Alexander J, Kobinger Gary P. Airway delivery of an adenovirus-based Ebola virus vaccine bypasses existing immunity to homologous adenovirus in nonhuman primates. J Virol 2013; 87:3668-77.
21. Yang ZY, Wyatt Linda S, Kong WP, Moodie Z, Moss B, Nabel Gary J. Overcoming immunity to a viral vaccine by DNA priming before vector boosting. J Virol 2003; 77:799-803.
22. Kibuuka H, Kimutai R, Maboko L, et al. A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-Uninfected East Africans (RV 172). J Infect Dis 2010; 201:600-7.
23. Gudmundsdotter L, Nilsson C, Brave A, et al. Recombinant modified vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity. Vaccine 2009; 27:4468-74.
24. Sullivan Nancy J, Martin Julie E, Graham Barney S, Nabel Gary J. Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule. Nat Rev Microbiol 2009; 7:393-400.
25. Wong G, Richardson Jason S, Pillet S, Patel A, Qiu X, Alimonti J, et al. Immune parameters correlatewith protection against ebola virus infection in rodents and nonhuman primates. Sci Transl Med 2012; 4:158ra146.
26. Sullivan Nancy J, Hensley L, Asiedu C, et al. CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates. Nat Med 2011; 17:1128-31.
27. Marzi A, Engelmann F, Feldmann F, et al. Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates. ProcNatl Acad SciU S A 2013; 110:1893-8.
28. Shedlock Devon J, Aviles J, Talbott Kendra T, et al. Induction of broad cytotoxic T cells by protective DNA vaccination against Marburg and Ebola. Mol Ther 2013; 21:1432-44.
29. Richardson Jason S, Yao Michel K, Tran Kaylie N, et al. Enhanced protection against Ebola virus mediated by an improved adenovirus-based vaccine. PLoS One 2009; 4:e5308.
30. Bello A, Tran K, Chand A, et al. Isolation and evaluation of novel adenoassociated virus sequences from porcine tissues. Gene Ther 2009; 16:1320-8.
31. Puppo A, Bello A, Manfredi A, et al. Recombinant vectors based on porcine adeno-associated viral serotypes transduce the murine and pig retina. PLoS One 2013; 8:e59025.
32. Bray M, Davis K, Geisbert T, Schmaljohn C, Huggins J. A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J Infect Dis 1998; 178:651-61.
33. Ebihara H, Theriault S, Neumann G, et al. In vitro and in vivo characterization of recombinant Ebola viruses expressing enhanced green fluorescent protein. J Infect Dis 2007; 196(suppl):S313-22.
34. Khan Amir S, Pope Melissa A, Draghia-Akli R. Highly efficient constant-current electroporation increases in vivo plasmid expression. DNA Cell Biol 2005; 24:810-8.
35. Grant-Klein RJ, Van Deusen NM, Badger Catherine V, Hannaman D, Dupuy Lesley C, Schmaljohn Connie S. A multiagent filovirus DNA vaccine delivered by intramuscular electroporation completely protects mice from Ebola and Marburg virus challenge. Hum Vaccin Immunother 2012; 8:1703-6.
36. Vanderzanden L, Bray M, Fuller D, et al. DNA vaccines expressing either the GP or NP genes of Ebola virus protect mice from lethal challenge. Virology 1998; 246:134-44.
37. Geisbert Thomas W, Bailey M, Hensley L, et al. Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challenge. J Virol 2011; 85:4222-33.
38. Donaldson Mitzi M, Kao S-F, Eslamizar L, et al. Optimization and qualification of an 8-color intracellular cytokine staining assay for quantifying T cell responses in rhesus macaques for pre-clinical vaccine studies. J Immunol Methods 2012; 386:10-21.
39. Faust Susan M, Bell P, Zhu Y, Sanmiguel J,Wilson James M. The role of apoptosis in immune hyporesponsiveness following AAV8 liver gene transfer. Mol Ther 2013; 21:2227-35.
40. Mays Lauren E, Wilson James M. The complex and evolving story of T cell activation to AAV vector-encoded transgene products. Mol Ther 2011; 19:16-27.
41. Oldenhove G, Bouladoux N, Wohlfert Elizabeth A, et al. Decrease of Foxp3+ Treg cell number and acquisition of effector cell phenotype during lethal infection. Immunity 2009; 31:772-86.
42. Dominguez-Villar M, Baecher-Allan CM, Hafler David A. Identification of T helper type 1-like, Foxp3+ regulatory T cells in human autoimmune disease. Nat Med 2011; 17:673-5.